Correction to: BMC Cancer (2018) 18:1198
DOI: 10.1186/s12885-018-5110-2
Following publication of the original article [1], the authors notified us of a typographical error in Table 1.
The corrected Table 1 is presented below.
Reference
Tan, et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. 2018, 2018;18:1198. https://doi.org/10.1186/s12885-018-5110-2.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Tan, WL., Ng, Q.S., Lim, C. et al. Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 18, 1288 (2018). https://doi.org/10.1186/s12885-018-5215-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12885-018-5215-7